Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 185

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

Open access
Koshkin, Vadim S., Barata, Pedro C., Zhang, Tian, George, Daniel J., Atkins, Michael B., Kelly, William J., Vogelzang, Nicholas J., Pal, Sumanta K., Hsu, JoAnn, Appleman, Leonard J., Ornstein, Moshe C., Gilligan, Timothy, Grivas, Petros, Garcia, Jorge A., Rini, Brian I. · 2018 · Journal for ImmunoTherapy of Cancer

Abstract

BACKGROUND: Nivolumab is approved for patients with metastatic renal cell carcinoma (mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in patients with non-clear cell RCC subtypes remains unknown as these patients were excluded from the original nivolumab trials. METHODS: Patients from 6 centers in the United States who received at least one dose of nivolumab for non-clear cell mRCC between 12/2015 and 06/2017 were identified. A retrospective analysis including patient characteristics, objective response rate according to RECIST v1.1 and treatment-related adverse events (TRAEs) was undertaken. RESULTS: Forty-one patients were identified. Median age was 58 years (33-82), 71% were male, and majority had ECOG PS 0 (40%) or 1 (47%). Histology included 16 papillary, 14 unclassified, 5 chromophobe, 4 collecting duct, 1 Xp11 translocation and 1 MTSCC (mucinous tubular and spindle cell carcinoma). Among 35 patients who were evaluable for best response, 7 (20%) had PR and 10 (29%) had SD. Responses were observed in unclassified, papillary and collecting duct subtypes. In the entire cohort, median follow-up was 8.5 months and median treatment duration was 3.0 months. Median PFS was 3.5 months and median OS was not reached. Among responders, median time to best response was 5.1 months, and median duration of response was not reached as only 2 out of 7 responders had disease progression during follow-up. TRAEs of any grade were noted in 37% and most commonly included fatigue (12%), fever (10%) and rash (10%). Nivolumab treatments were postponed in 34% and discontinued in 15% of patients due to intolerance. No treatment-related deaths were observed. CONCLUSIONS: Nivolumab monotherapy demonstrated objective responses and was well tolerated in a heterogeneous population of patients with non-clear cell mRCC. In the absence of other data in this treatment setting, this study lends support to the use of nivolumab for patients with metastatic non-clear cell renal cell carcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-018-0319-9

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 185

Metadata

Authors
Koshkin, V. S., Barata, P. C., Zhang, T., George, D. J., Atkins, M. B., Kelly, W. J., Vogelzang, N. J., Pal, S. K., Hsu, J., Appleman, L. J., Ornstein, M. C., Gilligan, T., Grivas, P., Garcia, J. A., & Rini, B. I.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2018-01-29
Volume
6
Issue
1
Pages
9-9
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2794685945
Cited by
185
References
1
FWCI
17.25
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. https://app.cochat.ai/papers/10.1186/s40425-018-0319-9
The paper
Koshkin, V. S., Barata, P. C., Zhang, T., George, D. J., Atkins, M. B., Kelly, W. J., Vogelzang, N. J., Pal, S. K., Hsu, J., Appleman, L. J., Ornstein, M. C., Gilligan, T., Grivas, P., Garcia, J. A., & Rini, B. I. (2018). Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-018-0319-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.